AnaptysBio, Inc. (ANAB) Receives Consensus Recommendation of “Buy” from Analysts
Shares of AnaptysBio, Inc. (NASDAQ:ANAB) have received a consensus rating of “Buy” from the seven ratings firms that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $77.67.
ANAB has been the subject of a number of recent analyst reports. JMP Securities lifted their price target on shares of AnaptysBio from $45.00 to $82.00 and gave the company an “outperform” rating in a research report on Tuesday, October 10th. Credit Suisse Group raised their price objective on shares of AnaptysBio from $34.00 to $38.00 and gave the company an “outperform” rating in a research note on Friday, August 25th. Zacks Investment Research raised shares of AnaptysBio from a “sell” rating to a “hold” rating in a research note on Monday, July 17th. Robert W. Baird began coverage on shares of AnaptysBio in a research note on Monday, July 10th. They issued an “outperform” rating and a $36.00 price objective for the company. Finally, Royal Bank Of Canada began coverage on shares of AnaptysBio in a research note on Thursday, September 14th. They issued an “outperform” rating and a $40.00 price objective for the company.
In other news, major shareholder Ventures Vii L. P. Avalon sold 37,040 shares of the business’s stock in a transaction that occurred on Wednesday, July 26th. The shares were sold at an average price of $24.35, for a total transaction of $901,924.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Holdings A/S Novo sold 70,706 shares of the business’s stock in a transaction that occurred on Thursday, August 3rd. The stock was sold at an average price of $23.31, for a total transaction of $1,648,156.86. Following the sale, the insider now owns 3,009,949 shares of the company’s stock, valued at approximately $70,161,911.19. The disclosure for this sale can be found here. Insiders have sold a total of 1,133,940 shares of company stock valued at $24,223,316 in the last 90 days.
Several large investors have recently modified their holdings of ANAB. Artal Group S.A. lifted its position in shares of AnaptysBio by 459.4% during the 2nd quarter. Artal Group S.A. now owns 250,000 shares of the biotechnology company’s stock worth $5,983,000 after buying an additional 205,310 shares during the last quarter. JPMorgan Chase & Co. purchased a new stake in shares of AnaptysBio during the 1st quarter worth approximately $3,851,000. Geode Capital Management LLC purchased a new stake in shares of AnaptysBio during the 1st quarter worth approximately $1,522,000. Northern Trust Corp lifted its position in shares of AnaptysBio by 360.6% during the 2nd quarter. Northern Trust Corp now owns 60,042 shares of the biotechnology company’s stock worth $1,436,000 after buying an additional 47,005 shares during the last quarter. Finally, Spark Investment Management LLC lifted its position in shares of AnaptysBio by 113.5% during the 2nd quarter. Spark Investment Management LLC now owns 74,100 shares of the biotechnology company’s stock worth $1,773,000 after buying an additional 39,400 shares during the last quarter. Institutional investors and hedge funds own 71.35% of the company’s stock.
Shares of AnaptysBio (NASDAQ:ANAB) opened at 65.52 on Wednesday. AnaptysBio has a 12 month low of $15.17 and a 12 month high of $74.00. The stock has a 50 day moving average of $36.95 and a 200 day moving average of $27.78. The stock’s market cap is $1.33 billion.
AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.29. The company had revenue of $7.00 million for the quarter, compared to analyst estimates of $3.45 million. On average, equities analysts anticipate that AnaptysBio will post ($1.99) earnings per share for the current fiscal year.
AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
Receive News & Ratings for AnaptysBio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.